Greg Petersen Biography and Net Worth

Director of Plus Therapeutics


Greg B. Petersen occupies the position of President at BrookView Capital LLC, President at Brookview Capital Advisors and Chief Financial Officer of Activant Solutions Holdings, Inc. Mr. Petersen is also on the board of PROS Holdings, Inc., Mohawk Group, Inc., Plus Therapeutics, Inc. and Aterian, Inc.

In the past he was President for Texas Capital Advisors LLC, Chief Financial Officer at Q2 Holdings, Inc. and Chief Financial Officer & Executive VP-Operations at Q2 Software, Inc. (a subsidiary of Q2 Holdings, Inc.), Principal at Trilogy Enterprises, Inc. and Vice President-Finance of Versata Software, Inc. (a subsidiary of Trilogy Enterprises, Inc.), Chief Financial Officer & Executive Vice President at Activant Solutions, Inc., Chief Financial Officer for Lombardi Software, Inc., Managing Director-Corporate Development at American Airlines, Inc. and SVP-Planning & Business Development at RailTex, Inc.

He received an undergraduate degree from Boston College and an MBA from The Fuqua School of Business.

What is Greg Petersen's net worth?

The estimated net worth of Greg Petersen is at least $32,868.18 as of September 11th, 2023. Mr. Petersen owns 24,166 shares of Plus Therapeutics stock worth more than $32,868 as of November 5th. This net worth approximation does not reflect any other assets that Mr. Petersen may own. Learn More about Greg Petersen's net worth.

How do I contact Greg Petersen?

The corporate mailing address for Mr. Petersen and other Plus Therapeutics executives is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. Plus Therapeutics can also be reached via phone at 737-255-7194 and via email at [email protected]. Learn More on Greg Petersen's contact information.

Has Greg Petersen been buying or selling shares of Plus Therapeutics?

Greg Petersen has not been actively trading shares of Plus Therapeutics during the past quarter. Most recently, on Monday, September 11th, Greg Petersen bought 20,000 shares of Plus Therapeutics stock. The stock was acquired at an average cost of $1.70 per share, with a total value of $34,000.00. Following the completion of the transaction, the director now directly owns 24,166 shares of the company's stock, valued at $41,082.20. Learn More on Greg Petersen's trading history.

Who are Plus Therapeutics' active insiders?

Plus Therapeutics' insider roster includes Marc Hedrick (CEO), Robert Lenk (Director), Greg Petersen (Director), and Andrew Sims (CFO). Learn More on Plus Therapeutics' active insiders.

Are insiders buying or selling shares of Plus Therapeutics?

In the last year, Plus Therapeutics insiders bought shares 12 times. They purchased a total of 61,454 shares worth more than $103,477.40. In the last year, insiders at the sold shares 1 times. They sold a total of 2,068 shares worth more than $4,053.28. The most recent insider tranaction occured on September, 13th when Director Richard J Hawkins bought 4,000 shares worth more than $6,000.00. Insiders at Plus Therapeutics own 5.5% of the company. Learn More about insider trades at Plus Therapeutics.

Information on this page was last updated on 9/13/2024.

Greg Petersen Insider Trading History at Plus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/11/2023Buy20,000$1.70$34,000.0024,166View SEC Filing Icon  
10/27/2021Buy833$25.80$21,491.40View SEC Filing Icon  
8/12/2020Buy666$37.80$25,174.80666View SEC Filing Icon  
See Full Table

Greg Petersen Buying and Selling Activity at Plus Therapeutics

This chart shows Greg Petersen's buying and selling at Plus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Plus Therapeutics Company Overview

Plus Therapeutics logo
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $1.36
Low: $1.33
High: $1.45

50 Day Range

MA: $1.42
Low: $1.22
High: $1.85

2 Week Range

Now: $1.36
Low: $1.15
High: $2.78

Volume

19,367 shs

Average Volume

55,767 shs

Market Capitalization

$8.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69